At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 59 enrolled
Drug / intervention
Saline placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof-of-concept, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Assess the Prophylactic Antiviral Activity Against Influenza, Safety, Tolerability, and Pharmacokinetics of CD388 Via a Human Viral Challenge Model
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Aug 31, 2022·Updated Sep 19, 2024
In Brief
A Phase 2 clinical trial evaluating Saline placebo and CD388 for Influenza. Completed, enrolled 59 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the preventative antiviral activity of CD388, as compared to saline placebo, when administered as a single dose to healthy adult participants in a human viral challenge model of influenza.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited Kingdom
CollaboratorsJanssen Pharmaceuticals
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedAug 2022
Enrollment StartSep 2022
Primary CompletionJul 2023
TodayJul 2026
First PostedAug 31, 2022
Enrollment StartSep 9, 2022
Primary CompletionJul 17, 2023
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.8 years ago
Interventions
Saline placebodrug
Sterile normal saline for injection
CD388combination
CD388 liquid for injection